BILE acids, or their degradation products by the gut bacterial flora, may play a role in the pathogenesis of colorectal cancer (Hill, 1975) . In animals, intra-rectal instillations of taurocholic or lithocholic acids (Narisawa et al., 1974; Reddy et al. 1977) or oral administration of cholic acid (Cohen et al., 1980) significantly increase the rate of chemically induced intestinal tumours. These data led us to study the effect of dietary chenodeoxycholic acid (CDCA) in experimental carcinogenesis of the intestine, all the more as CDCA, orally administered for months and years, is used in the treatment of human gallstones.
Experimental design
Standard diet (Extralabo) supplemented or not with CDCA, was given to 40 hybrid Fl (C57BL6/DBA2) mice and 75 golden hamsters. Three concentrations of CDCA were used, 250 pt/106 in mice, 750 and 2500 pt/106 in hamsters. In cocarcinogenesis experiments, control or CDCAtreated animals received weekly s.c. injections of 1.2 dimethylhydrazine (DMH), 10 mg/kg in mice, 20 mg/kg in hamsters. Necropsies were performed on all sacrificed animals; some animals found dead and autolysed were not included in the results. Fisher's exact-probability and non-parametric U tests were respectively used to Administration of CDCA and DMH DMH was injected weekly for 20 weeks in mice, 18 weeks in hamsters fed with 750 pt/106 CDCA and their controls, 13 weeks in hamsters fed with 2500 Pt/106 CDCA and their controls. The mean time of CDCA administration was 37 weeks in mice, 24 weeks in low-dose hamsters, 19 weeks in high-dose hamsters. The distribution of colorectal lesions in the 3 experimental series is reported in the Table. In the mice all the lesions were located in the distal colon and rectum. Few mice had cancers (2/10 and 2/9 in control and CDCA-fed mice), but polyps were found in 7/10 and 7/9 of the animals. If all intestinal lesions are gathered, a statistically signifi-* Correspondence to Dr M. S. Martin. Our results show that CDCA given alone does not induce benign or malignant intestinal tumours in mice and hamsters. A definite conclusion is however hampered by the low number of experimental animals. In hamsters, the experiment was shortened by the liver toxicity of CDCA.
DIET AND INTESTINAL CARCINOGENESIS IN RODENTS
In hamsters, CDCA given at two different doses had no promoting effect on DMH-induced colorectal tumours. Here also, the value of our experiments was compromised by severe liver damage induced by both DMH and CDCA. The particular susceptibility of hamster liver to DMH had previously been reported (Winneker et al., 1977) . The one result suggesting a possible cocarcinogenic effect of CDCA is the increase of the total number of DMH-induced tumours in the mice. However, the difference is significant only if benign tumours are included. The difference could be entirely fortuitous. Sarval et al. (1979) found that orally administered CDCA (2000 pt/I 06) did not change the prevalence ofintestinal tumours induced by methylnitrosourea in the rat.
Extension of these results to the situation of CDCA-treated patients has to be made with extreme care. In our experiments, doses of CDCA were chosen to be equivalent to the human therapeutic dose, either on a body weight, or a body surface basis, taking into account the mean quantity of food ingested by animals. This quantity was probably not affected by CDCA toxicity, as the mean bodyweight gain was not reduced in CDCAtreated animals. Liver toxicity, which could interfere with the effect of CDCA on the colon, is lower in humanthan in rodents, which are less able to form the non-toxic sulphate ester of lithocholic acid. The main metabolites of CDCA are also different in man and rodents.
A systematic study of the incidence of intestinal lesion detected by endoscopy in CDCA-treated patients and suitable controls could be the best way to answer the question of the tumorigenic hazard of bile acids in human. 
